Not exact matches
For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR
tyrosine kinase inhibitors (TKIs),
such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.
Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR
inhibitors called
tyrosine kinase inhibitors (TKI),
such as erlotinib, gefitinib and afatinib.
The statement also makes recommendations for clinical guidance and research priorities,
such as optimal choice of EGFR
tyrosine kinase inhibitors (TKIs), management of brain metastasis, role of re-biopsies, and use of circulating free DNA (cfDNA) for molecular studies.
«In the near future, we'll likely see more medications specifically targeting receptors on cells involved in allergic reactions,
such as
tyrosine kinase inhibitors (mast cells), for dermatologic use.»